MVP.ASX: FY26 Full Year Results Investor Presentation
Key points
- Solid financial performance with strong cashflow generation
- Penthrox® volume growth in all regions
- Penthrox® addressable market expanded to children in Europe
- Higher in-market Penthrox® demand expected in FY27
- Strong balance sheet provides financial flexibility
Full summary
Medical Developments International Ltd announced its FY26 full-year results, highlighting solid financial performance with group revenue up 9% to $42.6 million, EBIT at $0.2 million, and free cash flow improving by $5.8 million. Penthrox® volume grew by 18% in Europe and 28% in the Australian hospital segment. The company expanded Penthrox® indication to children in Europe, approved and launched in the UK and European markets. A health economic study demonstrated Penthrox® use in hospital emergency departments enables cost and operational savings. The company expects higher in-market Penthrox® demand in FY27, driven by the paediatric indication in Europe and published health economic data.
Guidance
Higher in-market Penthrox® demand expected in FY27
Outlook
The company expects higher in-market Penthrox® demand in FY27, driven by the paediatric indication in Europe and published health economic data.
Summary generated by a large language model. Please interpret with care.